Business
Precigen Announces Dosing of First Patients with UltraCAR-T® Cells Manufactured Using Proprietary UltraPorator™ System in Ongoing PRGN-3005 and PRGN-3006 Phase 1 Clinical Trials
- First patients dosed with UltraPorator manufactured PRGN-3005 UltraCAR-T cells at University of Washington/Fred Hutchinson Cancer Research Center and
About this update from Precigen, Inc.
[{"type":"text","content":"- First patients dosed with UltraPorator manufactured PRGN-3005 UltraCAR-T cells at University of Washington/Fred Hutchinson Cancer Research Center and PRGN-3006 UltraCAR-T cells at Moffitt Cancer Center\n - UltraPorator system is an exclusive device and proprietary software solution for the scale-up of rapid and cost-effective, decentralized manufacturing of UltraCAR-T therapies\n\n\nGERMANTOWN, Md., Nov. 16, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical implementation of its UltraPorator™ system, a device exclusive to Precigen for the scale-up of rapid and cost-effective decentralized manufacturing of UltraCAR-T® therapies. Precigen and its clinical partners have now successfully dosed the first patients with UltraCAR-T cells manufactured using the UltraPorator system. The patients were dosed with PRGN-3005 UltraCAR-T cells in the intraperitoneal (IP) arm of the ongoing Phase 1 study for advanced ovarian cancer patients conducted in collaboration with the University of Washington/Fred Hutchinson Cancer Research Center and with PRGN-3006 UltraCAR-T cells in the ongoing Phase 1/1b study for patients with relapsed or refractory acute myeloid leukemia (AML) and higher risk myelodysplastic syndrome (MDS) conducted in collaboration with the Moffitt Cancer Center. UltraCAR-T eliminates ex vivo expansion, which reduces manufacturing time to allow for rapid next day administration of UltraCAR-T cells following non-viral gene transfer.\n\n \n \n \n \n \n \n\n \n\"Dosing the first patients with UltraCAR-T cells manufactured using our proprietary UltraPorator system in both of our UltraCAR-T trials represents a major advance in our ability to transform how personalized cancer therapies are manufactured and administered within a medical center's own labs. This milestone positions UltraPorator as the essential go-to platform for cell therapy manufacturing,\" said Helen Sabzevari, PhD, President and CEO of Precigen. \"Our long-term goal is to streamline the process of oncology drug manufacturing so that healthcare professionals can treat their patients as quickly as possible in a commercially viable and expedient way.\"\nUltraPorator is a high-throughput, semi-closed electroporatio...